Crohn ' s disease (CD) and ulcerative colitis (UC) are chronic immunologically mediated diseases with a progressive relapsing remitting course. There is considerable heterogeneity in disease course and accurate prediction of natural history has been challenging. The phenotypic implication of increasing genetic predisposition to CD or UC is unknown.
INTRODUCTION
We are witnessing changes in the therapeutic paradigms for management of Crohn ' s disease (CD) and ulcerative colitis (UC), which are complex diseases aff ecting an estimated 1.6 million Americans ( 1, 2 ) . Recognizing progressive bowel damage and the consequence of prolonged mucosal disruption, randomized trials have demonstrated that treating early on the course of the disease with effi cacious anti-tumor necrosis factor (anti-TNF) biologic therapies may result in superior outcomes and prevent complications ( 3 -5 ) . However, widespread adoption of such an approach is challenging owing to concerns regarding cost and safety ( 3, 6 ) . Genetic variants off er the promise of an unchanging, stable and readily available predictive tool if demonstrated to have strong prognostic implications for disease behavior and disease-related complications.
Advances in genetics have led to the identifi cation of 163 distinct genetic risk loci for either CD or UC; the vast majority of loci are shared between the two diseases ( 7 ) . While these variants correlate well with disease risk, albeit with modest odds ratios (OR), the implications of the genetic burden conferred by these loci
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on disease phenotype remains unexplored. Th e examination of genotype -phenotype correlations in infl ammatory bowel disease (IBD) have been mostly through candidate single-nucleotide polymorphism (SNP) analyses, using small cohorts of patients with signifi cant associations not withstanding correction for multiple testing, or have preceded recent genetic discovery using fi ne mapping ( 8, 9 ) . Recent such analyses have suggested that rather than examining the association between single SNPs and disease behavior in CD and UC ( 8 ) , a more comprehensive approach examining overall genetic burden may yield more meaningful results. Indeed, other infl ammatory diseases that share pathogenesis with IBD have demonstrated phenotypic implications to an increasing genetic burden ( 10, 11 ) . Chibnik et al. ( 10 ) genotyped 542 Caucasian rheumatoid arthritis (RA) patients for 31 validated RA risk loci and found an association between increasing genetic burden, seropositivity, and erosive changes in RA.
In this prospective study, we examined the phenotypic implications of a higher genetic risk burden for CD and UC using a novel genetic risk score (GRS) method. We demonstrate contrasting eff ects of genetics on disease behavior across CD and UC, suggesting diff erential contribution of genetics to disease phenotype for both diseases.
METHODS

Study cohort
We recruited adult patients, age > 18 years, with CD, UC, or indeterminate colitis in a prospective patient cohort, the prospective registry of IBD study at Massachusetts General Hospital (PRISM). All patients were interviewed by a study coordinator and provided detailed information regarding their disease, which was verifi ed by their treating physician. Disease location was classifi ed according to the Montreal classifi cation in CD as involving the ileum alone, colon alone, or ileocolonic with a modifi er for upper gastrointestinal tract involvement and perianal disease. Disease behavior was stratifi ed as infl ammatory, stricturing, or penetrating disease. Disease extent in UC was according to the Montreal classifi cation; patients with proctitis and left -sided colitis were collapsed into one stratum. Smoking status was classifi ed as current, never, or former smoker at enrollment into the study. We also obtained information on medication use including use of immunomodulators (azathioprine, 6-mercaptopurine, and methotrexate) and anti-TNF agents (infl iximab, adalimumab, certolizumab pegol). Disease phenotype and medication use was updated till August 2012. All patients provided informed consent and the study was approved by the Institutional Review Board of Partners Healthcare.
Genotyping and GRS calculation
Approximately 10 ml of blood was drawn from all patients for extraction of the buff y coat. Genotyping was then performed on the Illumina Immunochip at the Broad Institute (Cambridge, MA). Th is is a custom-designed genetic chip with nearly 200,000 fi nemapping loci that have previously described or have been putatively associated with a spectrum of infl ammatory diseases ( 12 ) . Th e weighted GRS was calculated by fi rst extracting the 163 distinct IBD risk loci. For each risk allele, the genetic burden conferred by it was calculated by multiplying the log OR of its association with disease from the recent expanded Immunochip analysis ( 7 ) and allele dose (wild type, heterozygous, or homozygous). Wild type was assigned a weight of 0, with weights of 1 and 2 for hetero-and homozygosity. Th e cumulative GRS was then calculating by adding the contribution of each of the risk loci ( Σ [log(OR) × allele dose (0,1,2)]. Th e CD GRS was restricted to the 140 CD risk alleles, whereas the UC-GRS included only the 133 UC risk alleles, with 120 SNPs shared across both diseases. Th e GRS was stratifi ed into quartiles for examination of a dose-dependent eff ect. Th e continuous GRS was used to calculate the P value for the trend across the strata.
Statistical analysis
Genotypic extraction and calculation of the GRS was performed using Plink V1.07 ( 13 ) . All SNPs met the Hardy -Weinberg equilibrium threshold of P > 0.001, genotyping call rate > 99 % , and genotyping success rate > 80 % . Continuous variables were summarized as medians and interquartile ranges, whereas categorical variables were expressed as proportions and compared using the chi-square test. Statistical analysis was performed using Stata 12.0 (StataCorp, College Station, TX). Linear regression analysis was performed with age at diagnosis as a dependent variable. For categorical outcomes of disease location, behavior, need for surgery, immunomodulator or anti-TNF therapy, logistic regression with genetic burden as a predictor variable was performed. We also performed analysis stratifi ed by the NOD2 locus, which has so far demonstrated the strongest phenotypic association ( 14 ) , as well as smoking status to examine potential gene -environment interactions. We also adjusted for the present of NOD2 variants in our multivariate model to demonstrate the eff ect of the GRS independent of the NOD2 locus. A P value < 0.05 indicated statistical signifi cance. To confi rm the robustness of our results, we repeated the logistic regression models using bootstrapping with 1,000 repetitions. We also divided our cohort into two equal random subsets of patients with CD and UC and compared the association between genetic burden and disease phenotype in both subcohorts.
RESULTS
Study cohort
Our study included 1,105 patients (697 CD, 408 UC) genotyped on the Illumina Immunochip. Th e median age of diagnosis was 24 years among those with CD and 27 years for UC with median follow-up aft er diagnosis of 10 and 8 years, respectively ( Table 1 ). Approximately 27 % of patients with CD and 21 % of those with UC had a family history of IBD, with 5 % having more than one fi rst-degree relative aff ected. A third of the CD patients had penetrating disease (31 % ); one-quarter had isolated colonic disease (26 % ), and a similar proportion had perianal disease (28 % ). Just over half the patients with ulcerative colitis (55 % ) had pancolitis. Immunomodulator use was frequent in both diseases, occurring
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Genetic Burden and Disease Phenotype in Inflammatory Bowel Disease in 72 % of those with CD and 58 % of those with UC. A total of 44 % of patients with CD and 9 % of those with UC underwent bowel resection. Th e median duration of disease was similar across all quartiles of genetic risk for both CD and UC ( P > 0.10 for both comparisons). Out of a possible 280 risk SNPs (140 SNPs × 0, 1, or 2 for each allele) in CD, the median allele number was 146, corresponding to a median unweighted allele count of 0.54 (interquartile range 0.52 -0.56). Among those with CD, 24 % were heterozygous and 7 % homozygous for a NOD2 polymorphism. Table 2 describes the association between GRS quartile and disease phenotype in CD. Th ere was a strong association between genetic burden and age at diagnosis. Compared with patients in the lowest quartile of GRS, those in the highest quartile had an age of onset nearly 5 years younger (25.4 years vs. 30.3 years, Regression co-effi cient − 4.9, 95 % confi dence interval (CI) − 7.7 to − 2.1; P trend 0.008) ( Figure 1 ). Similarly, higher genetic burden also correlated with ileal disease location. Just over two-thirds of those in the lowest quartile of GRS had ileal involvement with their CD compared with 82 % of those in the highest quartile ( P = 0.002). Th ere was a highly signifi cant linear trend across quartiles ( P < 0.0001). We also observed a trend toward complicated CD ( P trend 0.09), immunomodulator use ( P trend 0.07) and bowel resection ( P trend 0.05) with increasing GRS. However, the association with complicated disease and bowel resection were confounded by the association of the GRS with ileal disease location. Adjusting for disease location, rendered those associations non-signifi cant, and attenuated the trend toward immunomodulator use ( P trend 0.12). Interestingly, there was no diff erence in GRS based on family history of IBD ( P trend 0.49) or with history of IBD in multiple fi rst-degree relatives.
GRS and phenotype in CD
We then examined the fraction of the variance in disease phenotypes predicted by the GRS. Th e area under the curve for predicting ileal involvement in CD patients by the GRS was 0.60. However, the fraction of the disease variance (measured by the pseudo-R2) explained by the CD risk score was less than 5 % for both age at diagnosis and ileal location, suggesting that much of the variance in disease phenotype in CD remains unexplained by the IBD risk loci. Th e association (or lack thereof) between disease phenotypes and CD was similar aft er repeating the regression models by bootstrapping, as well aft er division of our cohort into two subsets.
Interactions with NOD2 and smoking status
Given the previously demonstrated phenotypic associations between the NOD2 locus and ileal fi brostenosing CD, we examined whether the GRS quartile interacts with any of the recently described six variants in the NOD2 locus ( 15 ) . We also examined gene -environment interactions by examining whether genetic burden diff erentially impacts phenotype based on smoking status. Th e GRS had similar infl uences on age of onset in individuals without any NOD2 variants (OR for Q4 vs. Q1: − 4.3, 95 % CI − 7.7 to − 0.8) as those with at least one NOD2 mutation (OR − 4.1, 95 % CI − 8.5 to 0.4). Th e association between GRS and ileal involvement was also stronger for patients without a NOD2 mutation compared with those with at least one variant. Interestingly, GRS quartile had a stronger infl uence on age of onset in never smokers ( − 5.0, 95 % CI − 8.2 to − 1.8) compared with ever smokers ( − 4.2, 95 % CI − 9.4 to 0.9).
GRS and phenotype in UC
In contrast to CD, the GRS did not predict age of diagnosis, extent of disease or severity defi ned as the need for immunomodulator, anti-TNF biologics, or colectomy in UC ( P trend for all > 0.20) ( Table 3 ). We observed a direct association between family history of IBD and genetic burden of UC. Patients in the highest quartile of GRS were twice as likely to have a fi rst-degree relative with a history of IBD (OR 1.9, 95 % CI 1.0 -3.9; P trend 0.03) ( Figure 2 ) compared with those with the lowest quartile of genetic burden. Patients in the highest GRS quartiles were also twice as likely to have two or more fi rst-degree relatives (OR 2.29, P = 0.18) with a non-signifi cant association due to small number of patients in this category.
DISCUSSION
In a large, prospectively followed and genotyped cohort of 1,105 patients with IBD, we demonstrate that increasing genetic burden of disease predisposes toward ileal disease location and early age of diagnosis in CD, with a weaker trend toward severe manifestations of disease infl uenced by the tendency for ileal involvement. In contrast, increasing genetic burden was more common in UC patients with an involved fi rst-degree relative, but had had no implications on disease phenotype or severity. A recent study by Jung et al. ( 8 ) examined the phenotypic implications of 53 CD risk alleles in a French cohort. Th e presence of NOD2 risk alleles was associated with early age of onset and ileal involvement. Phenotypic associations between the interleukin-23 receptor (IL23R) polymorphisms and colonic disease as well as 
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as the GRS approach to examining genotype -phenotype relationships in CD and UC. With recent strategies for the management of CD suggesting an early, aggressive approach with " top-down " therapy to prevent progressive bowel damage, there is increasing interest in prediction tools that may identify patients at high risk for adverse disease outcomes. Indeed, genotype promises to be a stable and readily available predictive tool. However, the low degree of variance explained by the burden of IBD genetic risk alleles on age of diagnosis and ileal location of CD suggests that known IBD risk alleles may be only weak determinants of phenotype of disease. Furthermore, the association between genetic burden and complicated disease, need for bowel surgery, immunomodulator or anti-TNF biologic therapies was infl uenced by the predisposition toward ileal involvement, and were no longer signifi cant on adjusting for disease location. As ileal disease is a clinical parameter that can be readily ascertained, there appears to be limited added utility of genotyping for known risk loci with intent of predicting disease course. Future studies examining potential genetic predictors of adverse disease outcomes should consider expanding analyses to additional loci not yet implicated as being IBD risk alleles. Th e dichotomy in eff ect between CD and UC is interesting. Despite the vast majority of the IBD risk loci being shared between the two diseases, known genetic risk alleles explain a smaller fraction of the disease variance in UC than CD ( 7, 20, 21 ) . Furthermore, the infl uence of genetics on disease phenotype in UC has yielded less consistent and weaker associations, similar to our analysis ( 9 ) . Th e susceptibility to environmental infl uences are also diff erent between the two diseases, suggesting that despite involvement of common pathways, CD and UC remain at least two distinct entities and require separate approaches to prediction of risk and modification of the environmental infl uences. Finally, epigenetic alterations have been described in IBD, with enrichment of methylation sites near genes involved in the Th 17 pathway ( 22 ) . Although one small study did not identify an association between cross-sectional disease activity or treatment and epigenetic alterations, larger prospective studies of the implications of epigenetic changes in CD and UC may shed further light on determinants of disease phenotypes and clinical course ( 22, 23 ) .
Th ere are a few limitations of our study. First, it was conducted at a single tertiary academic center and is thus likely skewed toward a cohort of patients with more severe disease as evidenced by a high frequency of use of immunomodulator or biologic therapy. Nevertheless, the lack of strong genetic predictors of disease phenotype even in a cohort enriched for adverse outcomes suggests that the contribution of the IBD risk alleles to infl uencing disease behavior is weak.
In conclusion, we demonstrate an association between increasing genetic burden and early age of onset in CD but not UC. A higher complement of disease risk loci also predisposes toward ileal involvement in CD independent of the NOD2 locus, but the variance explained by genetics on disease phenotype is weak. Further studies should expand variants examined to outside the IBD risk alleles as well as examine the infl uence of the dynamic external and internal environment (microbiome) and epigenetic changes on disease phenotype and behavior. Th is requires continued autophagy mutations at the ATG16L1 and IRGM loci and noninfl ammatory disease were not robust on replication in an independent cohort ( 8 ) . Weersma et al. ( 16 ) genotyped a large Dutch cohort for fi ve disease risk alleles, namely NOD2, IBD5, DLG5, ATG16L1, and IL23R. Increasing genetic burden quantifi ed in their study by assigning an equal weight to polymorphisms at each of the loci revealed an association with penetrating or stricturing behavior and need for surgery. However, their study pre-dated discovery of several newly identifi ed loci and also did not account for the potential diff erential strength of association conferred by the loci owing to varying eff ects on CD risk. Furthermore, associations with complicated disease in their study did not adjust for pre-disposition to ileal disease ( 16 ) . In our study, as was noted by Jung et al. ( 8 ) , adjusting for ileal location of CD neutralizes the associations observed with penetrating, fi bro-stenosing or surgical CD, suggesting little added clinical utility to genotyping.
Several studies have examined genetic predictors of age of onset of IBD and have yielded inconsistent results. Th e genetic risk allele with one of the strongest eff ect sizes on CD risk is the NOD2 locus. However, two studies by Abreu et al. ( 17 ) and Ahmad et al. ( 18 ) found no association between NOD2 carriage and age of onset of CD. In contrast, Annese et al. ( 19 ) found a dose-dependent eff ect of NOD2 with mean age of diagnosis of 33, 29, and 24 years among those with 0, 1, or 2 NOD2 mutations. In a Dutch cohort with genotyping restricted to fi ve disease-associated loci, increasing numbers of risk alleles was associated with diagnosis younger than 40 years of age ( 16 ) . Our study extends these previous fi ndings by confi rming that genetic burden predisposes to early age of diagnosis in CD, and that this eff ect is not infl uenced solely by the presence of the NOD2 locus as those with no NOD2 variants experienced a more robust eff ect of the GRS. Interestingly, the eff ect was also stronger among non-smokers, suggesting a possible complementary eff ect between genetics and environment on disease onset. Th ere are limited data on genetic determinants of age of onset in UC; our fi ndings suggest that genetic burden of UC risk loci may not predispose to early onset in UC.
Our study has several implications. To our knowledge, ours is the fi rst large study using the expanded Immunochip risk loci as well international collaborations and accrual of large cohorts of patients with genetic and detailed and longitudinal phenotypic data to develop accurate and clinically useful prediction tools.
